Réanimation

, Volume 22, Issue 1, pp 54–61 | Cite as

Admission en réanimation pour les cancers du poumon: quels patients pour quels bénéfices ?

  • A. -C. Toffart
  • L. Sakhri
  • L. Potton
  • C. Minet
  • P. Guillem
  • C. Schwebel
  • D. Moro-Sibilot
  • J. -F. Timsit
Mise au Point / Update

Résumé

Le cancer bronchopulmonaire (CBP) est la première cause de mortalité par cancer, tous sexes confondus. Depuis dix ans, le pronostic des patients porteurs d’un CBP, en particulier les adénocarcinomes, s’est amélioré avec le développement des thérapies ciblées. La survie des patients porteurs d’un CBP admis en réanimation est actuellement entre 50 et 70 % avec une survie à six mois de 30 %. Les patients peuvent être présentés au réanimateur lors du diagnostic ou au cours de l’évolution de la maladie tumorale. Les critères pronostiques liés à la pathologie cancéreuse sont le statut métastatique, le performance status, l’état de dénutrition et l’existence d’éventuelles mutations. Les éléments liés à la situation aiguë (admission pour insuffisance respiratoire ou sepsis, score de gravité élevé) apparaissent également associés à la mortalité. Cependant, ces éléments ne suffisent pas pour prendre la bonne décision. La discussion d’admission et de prise en charge des défaillances d’organes doit être collégiale, intégrant l’oncologue, le réanimateur, le patient et son entourage. En l’absence de certitude, une « réanimation d’attente » peut être expliquée et proposée. L’intensité des traitements doit être réévaluée après trois à cinq jours, la non-amélioration des défaillances d’organes à ce stade étant un élément pronostique discriminant. L’apport d’un séjour en réanimation sur la qualité de la vie gagnée n’a pas été suffisamment étudié.

Mots clés

Cancer bronchique Réanimation Défaillance d’organes Performance status Réanimation d’attente 

Intensive care unit admission for lung cancer: which patients and for which benefits?

Abstract

Lung cancer is the first cause of death from cancer. For 10 years, prognosis of lung cancer patients has improved with the development of targeted therapies, especially for adenocarcinoma. Survival of lung cancer patients admitted to the intensive care unit (ICU) is currently between 50 and 70%, with a 6-month survival of 30%. Admission to the ICU represents a major concern for the intensivist either at the time of diagnosis or during the course of the disease. Prognostic factors due to malignancy include metastatic status, performance status, malnutrition, and mutational status. Prognosticators related to the acute situation including acute respiratory failure or sepsis, and high severity score on admission also appear to be associated with mortality. However, although well established, these prognostic factors are not sufficient to make an adequate decision. The discussion about ICU admission and organ support should involve the oncologist, the intensivist, the patient, as well as his family. When prognosis is uncertain, “ICU trial” could be accepted under the condition of reappraisal of the level of care 3–5 days later. Absence of improvement in organ failure after the fifth day discriminates survivors from decedents. To date, only scarce data are available regarding quality of life and anti-cancer treatment for these patients after ICU admission.

Keywords

Lung neoplasm Intensive care unit Organ dysfunction Performance status ICU trial 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29PubMedCrossRefGoogle Scholar
  2. 2.
    Pene F, Aubron C, Azoulay E, et al (2006) Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients: a reappraisal of indications for organ failure supports. J Clin Oncol 24:643–649PubMedCrossRefGoogle Scholar
  3. 3.
    Soares M, Caruso P, Silav E, et al (2010) Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study. Crit Care Med 38:9–15PubMedCrossRefGoogle Scholar
  4. 4.
    Caruso P, Ferreira AC, Laureinzo CE, et al (2010) Short- and long-term survival of patients with metastatic solid cancer admitted to the intensive care unit: prognostic factors. Eur J Cancer Care (Engl) 19:260–266CrossRefGoogle Scholar
  5. 5.
    Nagy-Mignotte H, Guillem P, Vignoud L, et al (2012) Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: A retrospective study of 300 patients. Lung Cancer 78:112–120PubMedCrossRefGoogle Scholar
  6. 6.
    Sandler A, Gray R, Perry MC, et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550PubMedCrossRefGoogle Scholar
  7. 7.
    Kris MG, Kwiatkowski DJ, Iafrate AJ, et al (2011) Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI’s Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 29(suppl; abstr CRA7506)Google Scholar
  8. 8.
    Maemondo M, Inoue A, Kobayashi K, et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388PubMedCrossRefGoogle Scholar
  9. 9.
    Shaw AT, Yeap BY, Solomn BJ, et al (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12:1004–1012PubMedCrossRefGoogle Scholar
  10. 10.
    Shaw AT, Kim DW, Nakagawa K, et al (2012) Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALKpositive non-small cell lung cancer (NSCLC) (PROFILE 1007). ESMO 2012 Congress. Abstract LBA_PRGoogle Scholar
  11. 11.
    Kim DW, Ahn MJ, Shi Y, et al (2012) Updated results of a global phase ii study with crizotinib in advanced alk-positive non-small cell lung cancer (NSCLC). ESMO 2012 Congress. Abstract 1230PDGoogle Scholar
  12. 12.
    Slatore CG, Cecere LM, Letourneau JL, et al (2012) Intensive care unit outcomes among patients with lung cancer in the surveillance, epidemiology, and end results-medicare registry. J Clin Oncol 30:1686–1691PubMedCrossRefGoogle Scholar
  13. 13.
    Toffart AC, Minet C, Raynard B, et al (2011) Use of intensive care in patients with nonresectable lung cancer. Chest 139:101–108PubMedCrossRefGoogle Scholar
  14. 14.
    Groome PA, Bolejack V, Crowley JJ, et al (2007) The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:694–705PubMedCrossRefGoogle Scholar
  15. 15.
    Berghmans T, Pasleau F, Paesmans M, et al (2012) Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. Eur Respir J 39:9–28PubMedCrossRefGoogle Scholar
  16. 16.
    Soares M, Darmon M, Salluh JI, et al (2007) Prognosis of lung cancer patients with life-threatening complications. Chest 131:840–846PubMedCrossRefGoogle Scholar
  17. 17.
    Blot F, Guiguet M, Nitenberg G, et al (1997) Prognostic factors for neutropenic patients in an intensive care unit: respective roles of underlying malignancies and acute organ failures. Eur J Cancer 33:1031–1037PubMedCrossRefGoogle Scholar
  18. 18.
    Christodoulou C, Rizos M, Galani E, et al (2007) Performance status (PS): a simple predictor of short-term outcome of cancer patients with solid tumors admitted to the intensive care unit (ICU). Anticancer Res 27:2945–2948PubMedGoogle Scholar
  19. 19.
    Lilenbaum RC, Cashy J, Hensing TA, et al (2008) Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol 3:125–129PubMedCrossRefGoogle Scholar
  20. 20.
    Moro-Sibilot D, Pluquet E, Zalcman G, et al (2007) What treatment for a patient of PS 2-3 with stage IV non-small cell lung cancer?. Rev Mal Respir 24:6S120–6S124PubMedCrossRefGoogle Scholar
  21. 21.
    Moro-Sibilot D, Aubert A, Diab S, et al (2005) Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer. Eur Respir J 26:480–486PubMedCrossRefGoogle Scholar
  22. 22.
    Adam AK, Soubani AO (2008) Outcome and prognostic factors of lung cancer patients admitted to the medical intensive care unit. Eur Respir J 31:47–53PubMedCrossRefGoogle Scholar
  23. 23.
    Andrejak C, Terzi N, Thielen S, et al (2011) Admission of advanced lung cancer patients to intensive care unit: a retrospective study of 76 patients. BMC Cancer 11:159PubMedCrossRefGoogle Scholar
  24. 24.
    Roques S, Parrot A, Lavole A, et al (2009) Six-month prognosis of patients with lung cancer admitted to the intensive care unit. Intensive Care Med 35:2044–2050PubMedCrossRefGoogle Scholar
  25. 25.
    Azoulay E, Moreau D, Alberti C, et al (2000) Predictors of shortterm mortality in critically ill patients with solid malignancies. Intensive Care Med 26:1817–1823PubMedCrossRefGoogle Scholar
  26. 26.
    Thyrault M, Oppon J, Le Bourdiec S, et al (2002) Resuscitation management of patients with primary bronchopulmonary cancer. Presse Med 31:1446–1450PubMedGoogle Scholar
  27. 27.
    Soares M, Silva UV, Teles JM, et al (2010) Validation of four prognostic scores in patients with cancer admitted to Brazilian intensive care units: results from a prospective multicenter study. Intensive Care Med 36:1188–1195PubMedCrossRefGoogle Scholar
  28. 28.
    Reichner CA, Thompson JA, O’Brien S, et al (2006) Outcome and code status of lung cancer patients admitted to the medical ICU. Chest 130:719–723PubMedCrossRefGoogle Scholar
  29. 29.
    Soubani AO, Ruckdeschel JC (2011) The outcome of medical intensive care for lung cancer patients: the case for optimism. J Thorac Oncol 6:633–638PubMedCrossRefGoogle Scholar
  30. 30.
    Azoulay E, Alberti C, Bornstain C, et al (2001) Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support. Crit Care Med 29:519–525PubMedCrossRefGoogle Scholar
  31. 31.
    Ferrand E, Regneir B, Boles JM, et al (2010) Limitation et arrêt des traitements en réanimation adulte: actualisation 2009 des recommandations de la Société de réanimation de langue française. Réanimation 19:679–698CrossRefGoogle Scholar
  32. 32.
    Thiery G, Azoulay E, Darmon M, et al (2005) Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study. J Clin Oncol 23:4406–4413PubMedCrossRefGoogle Scholar
  33. 33.
    Groeger JS, Glassman J, Nierman DM, et al (2003) Probability of mortality of critically ill cancer patients at 72 h of intensive care unit (ICU) management. Support Care Cancer 11:686–695PubMedCrossRefGoogle Scholar
  34. 34.
    Pardon K, Deschepper R, Vander Stichele R, et al (2012) Expressed wishes and incidence of euthanasia in advanced lung cancer patients. Eur Respir J 40:949–956PubMedCrossRefGoogle Scholar
  35. 35.
    Fried TR, Bradley EH, Towle VR, et al (2002) Understanding the treatment preferences of seriously ill patients. N Engl J Med 346:1061–1066PubMedCrossRefGoogle Scholar
  36. 36.
    Azoulay E, Soares M, Darmon M, et al (2011) Intensive care of the cancer patient: recent achievements and remaining challenges. Ann Intensive Care 1:5PubMedCrossRefGoogle Scholar
  37. 37.
    Lecuyer L, Chevret S, Thiery G, et al (2007) The ICU trial: a new admission policy for cancer patients requiring mechanical ventilation. Crit Care Med 35:808–814PubMedCrossRefGoogle Scholar
  38. 38.
    Azoulay E, Afessa B (2006) The intensive care support of patients with malignancy: do everything that can be done. Intensive Care Med 32:3–5PubMedCrossRefGoogle Scholar
  39. 39.
    Schonfeld N, Timsit JF (2008) Overcoming a stigma: the lung cancer patient in the intensive care unit. Eur Respir J 31:3–5PubMedCrossRefGoogle Scholar
  40. 40.
    Jennens RR, Rosenthal MA, Mitchell P, et al (2002) Outcome of patients admitted to the intensive care unit with newly diagnosed small cell lung cancer. Lung Cancer 38:291–296PubMedCrossRefGoogle Scholar
  41. 41.
    Boussat S, El’rini T, Dubiez A, et al (2000) Predictive factors of death in primary lung cancer patients on admission to the intensive care unit. Intensive Care Med 26:1811–1816PubMedCrossRefGoogle Scholar
  42. 42.
    Larche J, Azoulay E, Fieux F, et al (2003) Improved survival of critically ill cancer patients with septic shock. Intensive Care Med 29:1688–1695PubMedCrossRefGoogle Scholar
  43. 43.
    Toffart AC, Pluquet E, Timsit JF, et al (2008) Bronchial carcinoma and intensive care]. Rev Pneumol Clin 64:250–256PubMedCrossRefGoogle Scholar
  44. 44.
    Pene F, Percheron S, Lemiale V, et al (2008) Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med 36:690–696PubMedCrossRefGoogle Scholar

Copyright information

© Société de réanimation de langue française (SRLF) and Springer-Verlag France 2012

Authors and Affiliations

  • A. -C. Toffart
    • 1
    • 2
  • L. Sakhri
    • 1
  • L. Potton
    • 3
  • C. Minet
    • 3
  • P. Guillem
    • 4
  • C. Schwebel
    • 3
    • 5
  • D. Moro-Sibilot
    • 1
    • 2
  • J. -F. Timsit
    • 3
  1. 1.Pôle cancérologie médecine aiguë et communautaire, UM oncologie thoraciquecentre hospitalier universitaire A.-MichallonGrenoble cedex 09France
  2. 2.Université Grenoble-I U823, institut A.-Bonniot, université J.-FourierGrenobleFrance
  3. 3.Pôle cancérologie médecine aiguë et communautaire, UM réanimation médicalecentre hospitalier universitaire A.-MichallonGrenoble cedex 09France
  4. 4.Pôle cancérologie médecine aiguë et communautaire, UM centre de coordination en cancérologiecentre hospitalier universitaire A.-MichallonGrenoble cedex 09France
  5. 5.Laboratoires des pharmaceutiques biocliniques U1039Université J.-Fourier Grenoble-IGrenobleFrance

Personalised recommendations